EP2600777A1 - Systèmes, procédés et dispositifs d'estimation ultrasonore du cancer et de la réponse à une thérapie - Google Patents
Systèmes, procédés et dispositifs d'estimation ultrasonore du cancer et de la réponse à une thérapieInfo
- Publication number
- EP2600777A1 EP2600777A1 EP11815395.6A EP11815395A EP2600777A1 EP 2600777 A1 EP2600777 A1 EP 2600777A1 EP 11815395 A EP11815395 A EP 11815395A EP 2600777 A1 EP2600777 A1 EP 2600777A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- microbubbles
- treatment
- tumor
- microbubble
- substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 144
- 238000000034 method Methods 0.000 title claims abstract description 41
- 201000011510 cancer Diseases 0.000 title abstract description 25
- 238000002560 therapeutic procedure Methods 0.000 title description 14
- 230000004044 response Effects 0.000 title description 12
- 238000011282 treatment Methods 0.000 claims abstract description 79
- 238000002604 ultrasonography Methods 0.000 claims abstract description 41
- 238000003384 imaging method Methods 0.000 claims abstract description 32
- 238000002347 injection Methods 0.000 claims abstract description 20
- 239000007924 injection Substances 0.000 claims abstract description 20
- 238000011394 anticancer treatment Methods 0.000 claims abstract description 7
- 229960000397 bevacizumab Drugs 0.000 claims description 55
- 102000005962 receptors Human genes 0.000 claims description 20
- 108020003175 receptors Proteins 0.000 claims description 20
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical class NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 claims description 17
- 150000002632 lipids Chemical class 0.000 claims description 15
- 239000000126 substance Substances 0.000 claims description 14
- 102000006495 integrins Human genes 0.000 claims description 12
- 108010044426 integrins Proteins 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 claims description 9
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 230000002209 hydrophobic effect Effects 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 3
- 238000002372 labelling Methods 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- 238000004945 emulsification Methods 0.000 claims description 2
- 238000011835 investigation Methods 0.000 claims description 2
- 210000005166 vasculature Anatomy 0.000 abstract description 37
- 238000001727 in vivo Methods 0.000 abstract description 10
- 238000012285 ultrasound imaging Methods 0.000 abstract description 9
- 239000002872 contrast media Substances 0.000 abstract description 7
- 230000002792 vascular Effects 0.000 abstract description 6
- 230000008685 targeting Effects 0.000 abstract description 5
- 230000031018 biological processes and functions Effects 0.000 abstract description 3
- 230000010412 perfusion Effects 0.000 description 29
- 241000699670 Mus sp. Species 0.000 description 23
- 238000002607 contrast-enhanced ultrasound Methods 0.000 description 12
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 10
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 10
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 10
- 239000007789 gas Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 208000008839 Kidney Neoplasms Diseases 0.000 description 7
- 108090001090 Lectins Proteins 0.000 description 7
- 102000004856 Lectins Human genes 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 230000004087 circulation Effects 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 239000002523 lectin Substances 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 238000011580 nude mouse model Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 101100133184 Caenorhabditis elegans nep-1 gene Proteins 0.000 description 3
- 206010029260 Neuroblastoma Diseases 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000002491 angiogenic effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000004088 microvessel Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- KAVGMUDTWQVPDF-UHFFFAOYSA-N perflubutane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)F KAVGMUDTWQVPDF-UHFFFAOYSA-N 0.000 description 3
- 229950003332 perflubutane Drugs 0.000 description 3
- 230000002688 persistence Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 241000282412 Homo Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229910018503 SF6 Inorganic materials 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000001085 differential centrifugation Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 230000005747 tumor angiogenesis Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 238000007476 Maximum Likelihood Methods 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 238000011122 anti-angiogenic therapy Methods 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 230000015624 blood vessel development Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- -1 cyclic RGD-peptides Chemical class 0.000 description 1
- 108010045325 cyclic arginine-glycine-aspartic acid peptide Proteins 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002961 echo contrast media Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- WRQGPGZATPOHHX-UHFFFAOYSA-N ethyl 2-oxohexanoate Chemical compound CCCCC(=O)C(=O)OCC WRQGPGZATPOHHX-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002608 intravascular ultrasound Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 238000004802 monitoring treatment efficacy Methods 0.000 description 1
- 238000012895 mono-exponential function Methods 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000013138 pruning Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- SFZCNBIFKDRMGX-UHFFFAOYSA-N sulfur hexafluoride Chemical compound FS(F)(F)(F)(F)F SFZCNBIFKDRMGX-UHFFFAOYSA-N 0.000 description 1
- 229960000909 sulfur hexafluoride Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 108010014765 tomato lectin Proteins 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000004865 vascular response Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/08—Detecting organic movements or changes, e.g. tumours, cysts, swellings
- A61B8/0833—Detecting organic movements or changes, e.g. tumours, cysts, swellings involving detecting or locating foreign bodies or organic structures
- A61B8/085—Detecting organic movements or changes, e.g. tumours, cysts, swellings involving detecting or locating foreign bodies or organic structures for locating body or organic structures, e.g. tumours, calculi, blood vessels, nodules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/48—Diagnostic techniques
- A61B8/481—Diagnostic techniques involving the use of contrast agent, e.g. microbubbles introduced into the bloodstream
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/221—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by the targeting agent or modifying agent linked to the acoustically-active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N7/02—Localised ultrasound hyperthermia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0039—Ultrasound therapy using microbubbles
Definitions
- the present disclosure relates generally to microbubbles, and, more particularly, to specially formulated microbubbles and methods for the production and use thereof.
- the present disclosure also relates to cancer assessment techniques, and, more particularly, ultrasonic assessment of tumor response to therapies using specially formulated microbubbles.
- VEGF vascular endothelial growth factor
- BV bevacizumab
- efficacy may vary depending on cancer type and individual patients.
- a patient may thus undergo treatment while tumor morphology is monitored in order to ascertain if the treatment is effective. During this time, the tumor may grow and/or the cancer may spread to other parts of the body if the treatment is ineffective.
- Microbubbles can be formulated with a specific surface chemistry in order to bind to molecular targets within a patient, such as, but not limited to, target receptors in a tumor.
- Microbubbles injected into the bloodstream of the patient can circulate and eventually bind to the target receptors.
- the bound microbubbles can then be imaged using high-frequency ultrasound to allow in vivo visualization of the vasculature in the region of interest (ROI) of the patient.
- ROI region of interest
- specially formulated microbubbles can be injected into the bloodstream of a patient, for example, a cancer patient undergoing a treatment specifically targeting a biological process in a tumor.
- the injected microbubbles can act as vascular contrast agents, which can subsequently be detected using high-frequency ultrasound imaging.
- the vascular contrast agents can act as vascular contrast agents, which can subsequently be detected using high-frequency ultrasound imaging.
- microbubbles can have diameters of 4-5 ⁇ and/or 6-8 ⁇ .
- the microbubbles can have a surface chemistry that allows them to bind to molecular targets in the tumor vasculature.
- the microbubbles can selectively adhere to endothelia expressing a target receptor.
- the selective adhesion can be used to quantify the tumor vasculature in vivo.
- imaging the adhered microbubbles with ultrasound an indication of how tumor vasculature is affected by a specific cancer treatment can be obtained.
- Such techniques can be used in a clinical setting for rapid determination of anti-cancer treatment efficacy for individual patients.
- a method for determining efficacy of treatment of a cancerous tumor in a patient can include, at a first time after administering the treatment to a patient, injecting a population of microbubbles into the patient.
- the population of microbubbles can be size- selected so as to have diameters within a specified range.
- Each microbubble can have a surface chemistry that targets receptor sites in the tumor.
- a field of view can be imaged using ultrasound so as to obtain a first image.
- the field of view can include at least a portion of the tumor.
- the method can further include, after the imaging, sending an ultrasonic pulse to the field of view so as to destroy the microbubbles therein.
- the ultrasonic pulse can have a higher intensity than the ultrasound waves used for the imaging.
- the field of view can be re-imaged using ultrasound so as to obtain a second image.
- the method can also include comparing the intensity of the first and second images so as to measure the number of
- microbubbles attached to the targeted receptor sites in the tumor attached to the targeted receptor sites in the tumor.
- a substance for investigation of the efficacy of an anti-cancer treatment can include a plurality of microbubbles in solution.
- Each microbubble can have a gas core surrounded by a lipid membrane.
- the lipid membrane can have a surface chemistry that binds to receptor sites in a cancerous tumor.
- the respective diameters of the plurality of microbubbles can be 4-5 ⁇ and/or 6-8 ⁇ .
- FIG. 1 A is a schematic diagram of a microbubble, according to one or more
- FIG. IB shows graphs of number percentage and volume percentage of microbubbles in size-selected populations, according to one or more embodiments of the disclosed subject matter.
- FIG. 1C is a graph of ultrasound intensity as a function of time for different size-selected microbubble populations, according to one or more embodiments of the disclosed subject matter.
- FIGS. 2A-2B are graphs of ultrasound intensity and half- life, respectively, as a function of microbubble concentration for different size-selected microbubble populations, according to one or more embodiments of the disclosed subject matter.
- FIG. 3A-3B are graphs of ultrasound intensity and half-life, respectively, as a function of microbubble population gas volume for different size-selected microbubble populations, according to one or more embodiments of the disclosed subject matter.
- FIG. 4 is a process flow diagram for ultrasonic assessment of tumor response to therapy, according to one or more embodiments of the disclosed subject matter.
- FIGS. 5A-5B are graphs of measured ultrasound intensities of in vivo control
- microbubbles and RGD-peptide microbubbles respectively, according to one or more
- FIG. 6A is a graph of percent change in relative blood volume after treatment with BV for the control microbubbles, according to one or more embodiments of the disclosed subject matter.
- FIG. 6B is a graph of percent change in molecular expression after treatment with BV for the RGD-peptide microbubbles, according to one or more embodiments of the disclosed subject matter.
- FIGS. 7A-7B show high frequency ultrasound images following bolus injections of size- selected microbubbles into mice implanted with SK-NEP-1 renal tumors and with NGP renal tumors, respectively, according to one or more embodiments of the disclosed subject matter.
- FIGS. 7C-7D are graphs of relative microbubble perfusion in SK-NEP-1 tumor regions and NGP tumor regions, respectively, as a function of time, according to one or more embodiments of the disclosed subject matter.
- FIG. 8A shows high frequency ultrasound images at day 0 of treatment of mice implanted with SK-NEP-1 renal tumors before (left) and after (right) ultrasonic burst pulse application with corresponding video intensity-time curves (below), according to one or more embodiments of the disclosed subject matter.
- FIG. 8B shows high frequency ultrasound images at day 3 of treatment of mice implanted with SK-NEP-1 renal tumors before (left) and after (right) ultrasonic burst pulse application with corresponding video intensity-time curves (below), according to one or more embodiments of the disclosed subject matter.
- FIG. 8C shows high frequency ultrasound images at day 0 of treatment of mice implanted with NGP renal tumors before (left) and after (right) ultrasonic burst pulse application with corresponding video intensity-time curves (below), according to one or more embodiments of the disclosed subject matter.
- FIG. 8D shows high frequency ultrasound images at day 3 of treatment of mice implanted with NGP renal tumors before (left) and after (right) ultrasonic burst pulse application with corresponding video intensity-time curves (below), according to one or more embodiments of the disclosed subject matter.
- FIGS. 8E-8F are graphs of relative targeted microbubble adhesion in SK-NEP-1 tumor regions and NGP tumor regions, respectively, as a function of time, according to one or more embodiments of the disclosed subject matter.
- FIG. 9A-9B are fluorescent images of SK-NEP-1 tumors injected with fluorescein- labeled lectin at day 0 and day 3, respectively, after the start of treatment, according to one or more embodiments of the disclosed subject matter.
- FIG. 9C-9D are fluorescent images of NGP tumors injected with fluorescein-labeled lectin at day 0 and day 3, respectively, after the start of treatment, according to one or more embodiments of the disclosed subject matter.
- FIGS. 10A-10B are graphs of estimated micro vessel density of SK-NEP-1 tumor vasculatures and NGP tumor vasculatures, respectively, as a function of time, according to one or more embodiments of the disclosed subject matter.
- FIGS. 10C-10D are graphs of estimated total vessel length of SK-NEP-1 tumor vasculatures and NGP tumor vasculatures, respectively, as a function of time, according to one or more embodiments of the disclosed subject matter.
- FIG. 11 is a graph of two-dimensional cross-sectional area of a tumor as a function of time, according to one or more embodiments of the disclosed subject matter.
- FIG. 12A is a graph of initial relative microbubble perfusion in SK-NEP-1 and NGP tumors, according to one or more embodiments of the disclosed subject matter.
- FIG. 12B is a graph of initial relative targeted microbubble adhesion in SK-NEP-1 and
- NGP tumors according to one or more embodiments of the disclosed subject matter.
- a microbubble 100 is a gas-filled sphere ranging in diameter from approximately ⁇ up to ⁇ .
- the microbubble 100 can include a shell 104, which can be a lipid, protein, polymer, or combination thereof.
- Shell 104 separates a gas 102 contained in the interior of the shell 104 from a liquid environment 106.
- a liquid environment can be a liquid solution used to form the microbubble 100, a solution used to store or hold the
- microbubble 100 or a biological fluid, such as the bloodstream of a patient.
- microbubbles When injected into the bloodstream, microbubbles can act as vascular contrast agents that are detectable using high-frequency ultrasound imaging.
- the unique ability to distinguish the presence of the microbubbles in circulation from endogenous blood and tissue allow them to be used as probes for mapping vasculatures, for example, tumor vasculatures.
- microbubbles can be modified to contain ligands on their surface so as to bind to molecular targets in the vasculature.
- the microbubbles, acting as ultrasound imaging contrast agents can be selectively adhered to endothelia expressing a target receptor in order to quantify the vasculature in vivo.
- it When applied to tumor vasculature, it can indicate how a particular cancer treatment affects tumor vasculature and thus provide a measure of the efficacy of treatment on a patient's tumor.
- such techniques could be used in a clinical setting for rapid determination of anti-cancer treatment efficacy with respect to cancerous tumors in individual patients.
- the ability to monitor changes in tumor vasculature during treatment can provide a more expedient determination of anti-cancer therapy efficacy.
- cancer patients can switch to alternative and potentially more effective treatments without wasting precious time on ineffective modalities.
- such techniques could be used to monitor vasculature changes in other bodily organs and/or structures beside cancerous tumors.
- cyclic arginine-glycine-aspartic acid (RGD) peptides is a ligand that binds to ⁇ 3 integrin receptors, which are up-regulated in angiogenic blood vessels.
- Microbubbles can be modified to contain these RGD peptides on their surface so as to function as probes for identifying areas of high ⁇ 3 integrin expression.
- the utilization of RGD-targeted and untargeted microbubbles can be used to study the changes in tumor vessel architecture and molecular expression on the surface of blood vessels, for example, after the administration of a therapeutic anti-cancer treatment.
- VEGF vascular endothelial growth factor
- BV bevacizumab
- BV bevacizumab
- the efficacy of BV varies based on cancer types and between individual patients.
- the lipid microbubbles described herein have enhanced detectability in vivo for vasculature perfusion and molecular imaging studies.
- Size-selected microbubbles e.g., between approximately 4 ⁇ and ⁇ in diameter, in particular, having diameters of 4-5 ⁇ or 6-8 ⁇
- microbubbles having diameters within a range of approximately 4 ⁇ -5 ⁇ and 6 ⁇ -8 ⁇ may produce greater contrast and have longer half-lives in circulation as compared to polydispersed samples that contain mostly microbubbles having diameters within a range of 1 ⁇ -2 ⁇ .
- the larger microbubbles enjoy a larger surface area than and thus may have a greater number of labels on the surface thereof.
- the larger diameter microbubbles may take up a greater amount of space in the blood vessels of the tumor vasculature. These features may result in greater adhesion strength to the targets in the vasculature for the larger diameter microbubbles than their smaller diameter counterparts.
- Microbubbles can be formulated by emulsifying a lipid formation with a hydrophobic gas, such as sulfur hexafluoride (SF 6 ) or perfluorobutane (PFB).
- a hydrophobic gas such as sulfur hexafluoride (SF 6 ) or perfluorobutane (PFB).
- the lipid formulation for the emulsification can include (in terms of lipid molar ratios) 90% of 1 ,2- distearoyl-sn-glycero-3-phosphocholine (DSPC), 5% of l,2-dipalmitoyl-sn-glycero-3- phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000], and 5% of 1 ,2-distearoyl-sn- glycero-3-phosphoethanolamine-N-[maleimide(polyethylene glycol)-2000] (DSPE-PEG2K- Mai).
- the maleimide group can serve as
- Microbubbles having diameters in the ⁇ to 2 ⁇ range comprise over 90% of freshly generated (or commercially available) lipid-coated microbubbles. However, these smaller microbubbles attenuate strongly without producing much backscatter during ultrasound imaging. These small diameter microbubbles thus act as a negative contrast agent. In contrast, microbubbles having diameters in the 4 ⁇ -5 ⁇ and 6 ⁇ -8 ⁇ size ranges are highly echogenic. In addition, these larger microbubbles exhibit longer contrast persistence. For example, microbubbles having a diameter in the 6 ⁇ -8 ⁇ size range can be circulated for greater than 15 minutes at a dose of 5x10 microbubbles/mL in a 0. lmL bolus. Thus, the magnitude and duration of ultrasound contrast enhancement can be strongly dependent on the microbubble size distribution.
- the total integrated contrast enhancement can be increased significantly (e.g., greater than 10 times) for microbubbles having a diameter of 6-8 ⁇ at a concentration of 5 x 10 7 microbubbles/bolus as compared with microbubbles having a diameter of 4-5 ⁇ at the same concentration.
- Microbubbles having a diameter of 1-2 ⁇ at any concentration may not measurably enhance the integrated ultrasound signal depth and may in fact contribute to signal attenuation. This effect is illustrated in FIG. 1C, where representative time-intensity curves are shown for each size-selected population after a ⁇ bolus injection of 5 x 10 7 microbubbles.
- the persistence (i.e., survival in vivo) in circulation can also have important effects on contrast enhancement, molecular imaging, and therapeutic strategies.
- the duration of the ultrasound contrast signal may be depend on, among other things, the rate of microbubble removal from circulation due to dissolution of the gas core, filtering by the patient's organs, and uptake by macrophages. As shown in FIGS. 2A-2B, for the same concentration, these larger microbubbles may also be more persistent (i.e., survive in vivo) in circulation than smaller microbubbles. However, as reflected in FIGS. 3A-3B, for the same microbubble population gas volume, circulation half-life of the microbubbles may be similar regardless of microbubble diameter.
- a method of determining efficacy of an anti-cancer treatment is shown.
- a population of microbubbles having diameters within the range from 4 ⁇ to ⁇ can be selected from a polydisperse solution for injecting into a patient at 402.
- a solution of microbubbles having a variety of diameters therein e.g., between 0.5 ⁇ and ⁇
- Microbubbles in the polydisperse solution can be size sorted using, for example, differential centrifugation at 406. In such a process, microbubbles can be separated by size based on their relative buoyancy in a centrifugal field.
- FIG. IB shows size distributions of size-selected microbubbles from such a process.
- the microbubble populations for the individual 1-2 ⁇ , 4-5 ⁇ , and 6-8 ⁇ samples are shown as number- weighted and volume-weighted size distributions.
- the polydisperse sample shown in FIG. IB is a microbubble solution that has not undergone differential centrifugation. A portion of the sorted microbubbles having diameters that result in echogenic
- microbubbles (i.e., in the range of 4-5 ⁇ and 6-8 ⁇ ) can be selected for injection at 408.
- the resulting size-selected microbubble population can have a mean diameter of, for example, 4.5 ⁇ .
- the microbubbles Prior to injection, the microbubbles can undergo a post-labeling process to provide peptide molecules on the microbubble surface for binding to target receptors in the desired vasculature. For example, when targeting ⁇ 3 receptors, cysteine-modified cyclic-RGD peptides can be mixed with the microbubbles, for example, at a ratio of 30: 1 (peptide :maleimide molar excess). For a control group (i.e., non-binding), RAD peptides can be mixed with the microbubbles.
- Incubation may be used to bind the peptides to the maleimide group on the microbubbles. Any unreacted peptides can be removed by appropriate washing. Cysteine can be added and a second incubation performed in order to "cap" any unreacted maleimide groups on the surfaces of the microbubbles.
- microbubbles can be injected into the patient after it is determined at 412 that a sufficient time has elapsed after treatment has commenced.
- injection of microbubbles at 414 can occur just prior to or just after beginning treatment on the patient so as to establish a base line value for the number of microbubbles that bind to receptor sites in the patient's tumor.
- size-selected RGD targeted microbubbles can be injected into the bloodstream of a patient.
- a tumor within the patient can be simultaneously (or subsequently) monitored by imaging with an ultrasound scanner.
- the injected microbubbles can be allowed to circulate through the patient for ten minutes before removing any free microbubbles from circulation.
- a low frequency destruction pulse can be applied from the ultrasound scanner to destroy any
- microbubbles that may be within the field of view at 420.
- Ultrasound images taken before the pulse at 418 and after the destruction pulse at 422 show differences in the image intensity proportional to the amount of targeted bubbles that are present in the vasculature. By comparing the images at 424, a determination can be made regarding the amount of microbubbles present in the tumor vasculature. Control injections using non-binding RAD-peptide bearing microbubbles can be used to correct for RGD-peptide microbubbles that have been passively or non- specifically retained in the tumor vasculature.
- the process (e.g., 414-426) can be repeated at 428 at a later time to determine the effect of the treatment on the growth of the tumor. If the treatment is ineffective, the tumor may continue to grow, thereby resulting in an increase in the number of receptor sites in the tumor. As a result, subsequent determinations at 424 at the later time may show an increase in the number of microbubbles present in the tumor vasculature. If the treatment is effective, the tumor may cease growing or may shrink, thereby resulting in the same number of receptor sites or a decrease in the number of receptor sites. As a result, subsequent determinations at 424 at the later time may show the same or decreased number of microbubbles in the tumor vasculature.
- the treatment is effective. If effective, the treatment may continue at 434. If ineffective, the treatment may be abandoned at 436 for an alternative treatment.
- the method of FIG. 4 may also be used with any other treatment to determine efficacy thereof on a cancerous tumor.
- vascular response blood volume, perfusion, and molecular expression
- two human cancer cell lines (SK-NEP and NGP) were implanted in nude mice and allowed to develop for five weeks.
- High-frequency ultrasound imaging of the tumors was performed at 40MHz using a Visualsonics Vevo 770 during bolus tail-vein injections of size-selected microbubble suspensions.
- the suspensions had a median microbubble diameter of 4.5 ⁇ .
- the bolus was 50 ⁇ and the concentration was 5x10 microbubbles/mL.
- the change in intensity of the ultrasound signal was used to determine the relative blood volume.
- Targeted microbubbles bearing cyclic RGD-peptides or cyclic RAD-peptides for the control microbubbles
- the mice were imaged at 0, 1, 3, and 5 days.
- Non-responsive tumors injected with RGD target microbubbles as well as tumors imaged after injection with the control microbubbles were far less affected.
- xenograft model systems were used with previously well-characterized responses to VEGF inhibition, i.e., a responder (SK-NEP-1) and a non-responder (NGP).
- the two tumor models have divergent responses to VEGF inhibition.
- Xenografts from the SK-NEP-1 human Ewing family tumor cell line are highly responsive to various anti-VEGF agents, with significant loss of vasculature and inhibition of growth.
- xenografts from the NGP human neuroblastoma cell line continue to grow with only slight restriction and minimally destabilized vessels.
- CEUS contrast-enhanced ultrasound imaging
- the identity of the neuroblastoma cell lines NGP and SK-NEP-1 were verified by STR profiling.
- the cell lines were stably transfected with FUW-Luciferase plasmid and were selected and maintained in lmg/ml neomycin.
- 1 x 10 6 cells were injected intrarenally into 4-6 week old NCR female nude mice. The resulting xenografts were monitored for growth using
- mice were randomized to control or treatment groups (cohort size 5-8 mice per modality and treatment groups).
- BV 0.5 mg was administered immediately after imaging on days 0 and 3. Animals were killed by C0 2 inhalation at indicated time points (at day 5 after serial imaging studies, and at days 0, 1, 3, and 5 for control and lectin perfusion analyses).
- mice were injected with fluorescein- labeled Lycopersicon esculentum lectin (100 ⁇ g/100 ⁇ l PBS).
- Vasculature was fixed by infusing 1% paraformaldehyde. 40-um sections were cut using a vibratome, and digital images subjected to computer-assisted quantitative analysis of tumor vessel architecture.
- Size-selected microbubbles described above were used for perfusion and molecular imaging. Lipid-coated, perfluorobutane-filled microbubbles were produced by mechanical agitation. For targeting, a maleimide group was included on the distal end of the polyethylene glycol group on the lipopolymer used to coat the microbubbles. Residual lipid was removed and 4.5- ⁇ median diameter microbubbles were isolated by centrifugation. Targeted microbubbles were then conjugated to cysteine-tagged RGD (target) or RAD (control) peptides and washed again to remove residual peptide. RGD conjugation was confirmed by HPLC and MALDI-TOF. Ultrasound imaging was performed using a small-animal ultrasound scanner with a 30-MHz transducer.
- mice were anesthetized and placed on a physiological monitoring platform, and their tail veins were catheterized for injections using a 27-gauge, 1 ⁇ 2-inch butterfly catheter.
- transducer was positioned at the tumor midsection, and 2-D ultrasound images were acquired using a field of view of 17x17 mm.
- a 50- ⁇ bolus (2.5xl0 7 microbubbles) followed by a 15- ⁇ , saline flush were injected while imaging at the maximum frame rate for respiratory gating ( ⁇ 11 frames/second) and 100% power.
- Maximum intensity persistence (MIP) images were acquired using non-targeted RAD-microbubbles.
- Contrast enhancement was detected using background subtraction from reference videos acquired before the microbubble injection.
- a time-intensity curve was generated from the MIP image stack by calculating the contrast enhancement within a region of interest (ROI) drawn around the hypoechoic tumor region.
- Relative microbubble perfusion (rmp) was defined as the maximum signal enhancement and determined by regression of a monoexponential function to the time -intensity curve during microbubble uptake.
- RAD- and RGD-microbubble injections were randomized.
- the rtma was a measurement of the contrast enhancement within the ROI from only targeted microbubbles, and it did not include contributions from tissue motion, freely circulating microbubbles or nonspecifically adherent microbubbles.
- a linear mixed effects regression model was used that estimates linear trajectories for each cohort over time, while accounting for comparisons among repeated measurements from the same mice.
- the intercept was treated as a random effect and covariate to account for the differences between mice at baseline.
- the maximum likelihood method was used for estimation of the regression coefficients.
- the ultrasound perfusion imaging employed a linear model for the raw data at days 0, 1, 3, and 5, using the slope of linear fit for comparison between cohorts.
- the ultrasound targeted imaging implemented a non- linear model including random effects.
- the data for each mouse was normalized to the initial value to account for differences in baseline. The data was then fit to an exponential decay (e "kt ) ' The decay constant (k) term was used for comparison between cohorts.
- Xenografts formed in the kidney of NCR nude mice with the human Ewing family tumor cell line SK-NEP-1 are highly sensitive to VEGF blockade therapy, while human neuroblastoma NGP cell lines are much less responsive to VEGF blockade therapy.
- the intrarenally implanted xenograft tumors were monitored for growth and randomly assigned to biweekly injections of anti-VEGF antibody BV or vehicle. Cohorts of tumor-bearing animals were serially imaged at day 0 (pretreatment), and days 1, 3, and 5 after the first drug injection. To confirm the characterization of responsiveness, 2-D tumor area was measured by ultrasonography, the results of which are shown in FIG. 11.
- the tumor 2-D cross-sectional area was determined from the ultrasound images using Visualsonics software. Area measurements of the tumor were calculated from the ultrasound images using a ROI that encompassed the hypoechoic region of the kidney (tumor tissue). All area measurements were performed in the midsection of the tumor.
- BV treatment significantly arrested tumor growth in SK-NEP-1 xenografts at days 3 and 5 in comparison to control, but not in NGP xenografts.
- treatment of SK-NEP-1 mice with BV essentially arrested tumor growth over the 5 day period (i.e., ultrasound -5%), as compared with continued growth in the control tumors (i.e., ultrasound +42%).
- NGP tumors were unaffected by BV treatment (i.e., ultrasound +44% vs. +97%, BV vs. control).
- Microbubble contrast agents exhibit hemodynamics similar to erythrocytes, allowing measurement of blood flow using ultrasound (see FIGS. 7A-7B). Size-selected microbubbles optimized for perfusion imaging were used. NCR Nude mice implanted with either NGP or SK- NEP-1 renal tumors were imaged with high-frequency ultrasound following bolus injections of size-selected microbubbles. Mice were imaged at 0, 1, 3, and 5 days. Bevacizumab (BV) or albumin (Con) were administered immediately after the imaging sessions on days 0 and 3.
- BV Bevacizumab
- Con albumin
- Representative tumors with microbubble perfusion overlays from the SK-NEP-1 and NGP groups are shown at day 0 and day 3. Hypoechoic tumor regions are outlined in white and regions of microbubble perfusion are colored green (i.e., spots within the outlined region in the figures). In contrast to the SK-NEP-1 Con, NGP Con, and NGP BV groups, the BV-treated SK- NEP-1 tumors showed no increase in size or microbubble perfusion.
- Relative microbubble perfusion was measured for each animal prior to treatment.
- CEUS perfusion imaging showed that BV treatment arrested the increase in microbubble perfusion in responder SK-NEP-1 tumors, but not in NGP xenografts.
- CEUS was also used to monitor ⁇ 3 integrin, which is expressed preferentially on actively proliferating vessels found in growing tumors.
- Microbubbles were targeted to this epitope by surface conjugation of RGD peptide (RAD peptide serving as control).
- Relative targeted microbubble adhesion (rtma) was quantified by the decrease in tumor pixel intensity following the ultrasound microbubble -burst pulse (versus RAD control) (see FIGS. 8A-8F).
- the expression of ⁇ ⁇ ⁇ 3 integrin in the vessels of the tumor region was evaluated in the same mice using CEUS with RGD-labeled microbubbles (versus RAD control). Representative tumors with microbubble contrast overlays from the SK-NEP-1 and NGP groups are shown at day 0 and day
- FIGS. 8A-8D Images are shown before (left) and after (right) the burst pulse was applied to fragment the microbubbles in the field of view for FIGS. 8A-8D.
- the corresponding video intensity-time curve is shown below each pair of images for both RGD-labeled (top trace) and RAD-labeled (bottom trace) microbubble injections.
- BV-treated SK-NEP-1 mean rtma did not change significantly after 1 day, but it decreased 91 ⁇ 5% (P ⁇ 0.00001) by day 3 and 99 ⁇ 5% (P ⁇ 0.00001) by day 5.
- the mean rtma values decreased also for BV -treated NGP and control mice, but at slower rates.
- the decay rates were compared using a non-linear exponential decay model (see FIGS. 8E-8F). The rtma was quantified in the tumor region on days 0, 1, 3, and 5.
- FIGS. 9A-9D are representative fluorescent images at days 0 and 3 of BV treatment. After binarization of the images, microvessel density (MVD) was estimated by the total number of white pixels per field. The results shown in FIGS. 10A-10B are as the mean pixel count per image + SD. BV significantly decreased MVD in SK-NEP-1 at Days 1, 3, 5 (*p ⁇ 0.003), but not in NGP.
- Control SK-NEP-1 and NGP tumor perfusion also did not change over the experimental period.
- vascular area is calculated from total pixels, large-diameter vessels contributed disproportionately to MVD as compared to fine capillaries.
- total length can be calculated by skeletonizing images and then scoring these by computer.
- New vascular branches can form a dynamic and relatively VEGF-dependent element in angiogenic networks.
- BV treatment thus reduced overall perfusion in SK-NEP-1 tumors, with disproportionate pruning of smaller, branch vessels.
- BV decreases microvessel density (MVD), vessel length, and total vessel number in SK-NEP-1 tumors, but not NGP tumors.
- Prognostic imaging biomarkers mean relative microbubble perfusion (proportional to total blood flow) and relative targeted microbubble adhesion (proportional to ⁇ 3 integrin concentration on the luminal surface of the endothelium)
- cancer e.g., humans or other animal
- ultrasound is well-suited for real-time assessment in animals and humans, both children and adults, with inexpensive, widely available, and portable equipment, and rapid imaging times.
- microbubbles targeted to cancer endothelial biomarkers may allow CEUS imaging to provide a first-line modality for diagnosing and monitoring cancer angiogenesis.
- alternate regimens could be considered without waiting for overt therapeutic failure to occur, avoiding needless toxicity.
- those patients whose tumors demonstrated responsiveness could remain on treatment.
- such early assessment of drug effectiveness could reduce the economic strains of cancer treatment for patients and families.
- the methods, systems, and devices of the present disclosure are applicable to other treatments as well.
- the microbubbles can be used in the imaging of other types of tumors beyond those described herein.
- the microbubbles can be used to monitor the efficacy of a variety of conditions, treatments, and diseases, as well as different types of cancer/tumors.
- embodiments and teachings of the present disclosure are applicable to more than just monitoring treatment efficacy. Rather, the teachings and embodiments of the disclosed subject matter may be applied to health monitoring of patient vasculature or any other in vivo vasculature inspection application, according to one or more contemplated embodiments.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Epidemiology (AREA)
- Acoustics & Sound (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Selon l'invention, des microbulles peuvent être injectées dans le flux sanguin d'un patient, par exemple d'un patient souffrant d'un cancer et soumis à un traitement ciblant spécifiquement un processus biologique dans une tumeur. Les microbulles injectées peuvent agir en tant qu'agents de contraste vasculaire, qui peuvent être détectés in vivo à l'aide d'une imagerie ultrasonore à haute fréquence. Les microbulles peuvent avoir une chimie de surface qui leur permet de se lier à des cibles moléculaires dans le système vasculaire tumoral. Après injection, les microbulles peuvent adhérer sélectivement à des endothélia exprimant un récepteur cible. L'adhérence sélective peut être utilisée pour quantifier le système vasculaire tumoral in vivo. L'imagerie par ultrasons des microbulles adhérentes indique le degré d'incidence qu'un traitement spécifique anti-cancéreux peut avoir sur le système vasculaire tumoral. De telles techniques peuvent être utilisées dans des conditions cliniques pour une détermination rapide de l'efficacité du traitement anticancéreux pour des patients individuels.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37109110P | 2010-08-05 | 2010-08-05 | |
PCT/US2011/046830 WO2012019146A1 (fr) | 2010-08-05 | 2011-08-05 | Systèmes, procédés et dispositifs d'estimation ultrasonore du cancer et de la réponse à une thérapie |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2600777A1 true EP2600777A1 (fr) | 2013-06-12 |
Family
ID=45559848
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP11815395.6A Withdrawn EP2600777A1 (fr) | 2010-08-05 | 2011-08-05 | Systèmes, procédés et dispositifs d'estimation ultrasonore du cancer et de la réponse à une thérapie |
Country Status (3)
Country | Link |
---|---|
US (1) | US20130251633A1 (fr) |
EP (1) | EP2600777A1 (fr) |
WO (1) | WO2012019146A1 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10058837B2 (en) | 2009-08-28 | 2018-08-28 | The Trustees Of Columbia University In The City Of New York | Systems, methods, and devices for production of gas-filled microbubbles |
KR101323329B1 (ko) | 2011-11-22 | 2013-10-29 | 삼성메디슨 주식회사 | 초음파 영상 표시 방법 및 초음파 영상 표시 장치 |
CN104303184B (zh) * | 2012-03-21 | 2018-05-15 | 皇家飞利浦有限公司 | 整合医疗成像和活检数据的临床工作站以及使用其的方法 |
US9949722B2 (en) * | 2013-12-03 | 2018-04-24 | University Of Virginia Patent Foundation | System and method for binding dynamics of targeted microbubbles |
US20190030374A1 (en) | 2014-12-19 | 2019-01-31 | Universite Pierre Et Marie Curie (Paris 6) | Implantable ultrasound generating treating device for brain treatment, apparatus comprising such device and method implementing such device |
KR102617894B1 (ko) * | 2015-11-05 | 2023-12-26 | 삼성메디슨 주식회사 | 초음파 진단 장치 및 초음파 영상을 생성하기 위한 방법 |
HUE059596T2 (hu) * | 2015-11-11 | 2022-12-28 | Navifus Co Ltd | Agydaganat kezelésének módszere és készlete ultrahangos rendszer segítségével |
ES2912885T3 (es) | 2016-03-11 | 2022-05-30 | Univ Sorbonne | Dispositivo de tratamiento externo de generación de ultrasonidos para el tratamiento de la médula espinal y de los nervios espinales |
EP3426347B1 (fr) | 2016-03-11 | 2024-05-15 | Sorbonne Universite | Dispositif de traitement implantable générant des ultrasons pour le traitement de la moelle épinière et appareil comprenant un tel dispositif |
CN113521317B (zh) * | 2021-07-01 | 2023-03-31 | 中国科学院深圳先进技术研究院 | 一种双靶向肿瘤的超声分子复合成像方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7083778B2 (en) * | 1991-05-03 | 2006-08-01 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
US6261537B1 (en) * | 1996-10-28 | 2001-07-17 | Nycomed Imaging As | Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors |
CA2513044A1 (fr) * | 2002-03-01 | 2004-08-05 | Dyax Corp. | Peptides de liaison kdr et vegf/kdr et leur utilisation a des fins diagnostiques et therapeutiques |
WO2005039526A1 (fr) * | 2003-08-18 | 2005-05-06 | Wei Wu | Procede, reactif et dispositif permettant d'emboliser des vaisseaux capillaires dans une tumeur au moyen d'un reactif supersonique a petites bulles |
US7758594B2 (en) * | 2005-05-20 | 2010-07-20 | Neotract, Inc. | Devices, systems and methods for treating benign prostatic hyperplasia and other conditions |
US20080311045A1 (en) * | 2007-06-06 | 2008-12-18 | Biovaluation & Analysis, Inc. | Polymersomes for Use in Acoustically Mediated Intracellular Drug Delivery in vivo |
-
2011
- 2011-08-05 WO PCT/US2011/046830 patent/WO2012019146A1/fr active Application Filing
- 2011-08-05 EP EP11815395.6A patent/EP2600777A1/fr not_active Withdrawn
- 2011-08-05 US US13/813,236 patent/US20130251633A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO2012019146A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2012019146A1 (fr) | 2012-02-09 |
US20130251633A1 (en) | 2013-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20130251633A1 (en) | Systems, methods, and devices for ultrasonic assessment of cancer and response to therapy | |
Wang et al. | Targeting of microbubbles: contrast agents for ultrasound molecular imaging | |
Sirsi et al. | Contrast ultrasound imaging for identification of early responder tumor models to anti-angiogenic therapy | |
Fan et al. | Antiangiogenic-targeting drug-loaded microbubbles combined with focused ultrasound for glioma treatment | |
Carlier et al. | Vasa vasorum imaging: a new window to the clinical detection of vulnerable atherosclerotic plaques | |
Kim et al. | Direct imaging of cerebral thromboemboli using computed tomography and fibrin-targeted gold nanoparticles | |
Rojas et al. | Ultrasound molecular imaging of VEGFR-2 in clear-cell renal cell carcinoma tracks disease response to antiangiogenic and notch-inhibition therapy | |
Hyvelin et al. | Use of ultrasound contrast agent microbubbles in preclinical research: recommendations for small animal imaging | |
Leguerney et al. | Molecular ultrasound imaging using contrast agents targeting endoglin, vascular endothelial growth factor receptor 2 and integrin | |
Wang et al. | Ultrasound molecular imaging of angiogenesis using vascular endothelial growth factor-conjugated microbubbles | |
Caskey et al. | Leveraging the power of ultrasound for therapeutic design and optimization | |
Rojas et al. | In vivo molecular imaging using low-boiling-point phase-change contrast agents: a proof of concept study | |
Dr. Eichhorn et al. | Vascular targeting tumor therapy: non-invasive contrast enhanced ultrasound for quantitative assessment of tumor microcirculation | |
Wang et al. | Ultra–Low-Dose Ultrasound Molecular Imaging for the Detection of Angiogenesis in a Mouse Murine Tumor Model: How Little Can We See? | |
Nakatsuka et al. | In vivo ultrasound visualization of non-occlusive blood clots with thrombin-sensitive contrast agents | |
US20230270413A1 (en) | Composition and methods for sensitive molecular analysis | |
Daeichin et al. | Quantification of endothelial αvβ3 expression with high-frequency ultrasound and targeted microbubbles: in vitro and in vivo studies | |
Diakova et al. | Targeted ultrasound contrast imaging of tumor vasculature with positively charged microbubbles | |
Wang et al. | Ultrasound-based measurement of molecular marker concentration in large blood vessels: a feasibility study | |
Paradossi et al. | In vivo toxicity study of engineered lipid microbubbles in rodents | |
Pollard et al. | Quantitative contrast enhanced ultrasound and CT assessment of tumor response to antiangiogenic therapy in rats | |
Wang et al. | Prolonging the Ultrasound Signal Enhancement From Thrombi Using Targeted Microbubbles Based on Sulfur-Hexafluoride–Filled Gas | |
Oddo et al. | In vivo biodistribution of engineered lipid microbubbles in rodents | |
Goncin et al. | Rapid copper-free click conjugation to lipid-shelled microbubbles for ultrasound molecular imaging of murine bowel inflammation | |
Omoto et al. | New method of sentinel node identification with ultrasonography using albumin as contrast agent: a study in pigs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20130305 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20150303 |